A number of cytochrome P450 (CYP)3A phenotyping probes have been used to characterize the drug interaction potential of new molecular entities; of these, midazolam has emerged as the gold standard. Recently, plasma 4β-hydroxycholesterol (4β-OHC), the metabolite of CYP3A-mediated cholesterol metabolism, has been championed as an endogenous biomarker for CYP3A, particularly during chronic conditions where CYP3A activity is altered by disease and in long-term treatment studies where midazolam administration is not optimal. Multiple studies in humans have shown that 4β-OHC can qualitatively differentiate among weak, moderate, and potent CYP3A induction when an inducer, typically rifampin, is administered for up to 2 weeks. Conversely, longer durations of CYP3A inhibitor administration (ࣙ1 month) appear to be necessary to differentiate among weak, moderate, and potent CYP3A inhibitors. A number of studies have reported statistically significant linear relationships between 4β-OHC plasma concentrations (and 4β-OHC:cholesterol ratios) and midazolam clearance. However, sufficiently powered studies assessing the ability of 4β-OHC or 4β-OHC:cholesterol ratios to measure CYP3A activity (ie, predictive performance) have not been conducted to date. Additional limitations associated with 4β-OHC phenotyping include inability to detect acute changes in CYP3A activity, uncertainty with regard to its intestinal formation, ambiguity surrounding the role of CYP3A5 in its metabolism, and lack of clarity regarding the role of transporters in its disposition. As such, the data do not support the use of 4β-OHC or 4β-OHC:cholesterol ratios as an endogenous biomarker for CYP3A activity.
Cytochrome P450 (CYP)3A is expressed in the liver and small intestine and is responsible for metabolizing over 50% of all marketed drugs. 1 The majority of CYP3A is accounted for by CYP3A4, although functional CYP3A5 (CYP3A5*1), is expressed in approximately 70% of black and 20% of white individuals. 2, 3 Because CYP3A genotypes that confer poor or ultrarapid metabolizer status have not been identified to date, CYP3A phenotyping remains an important tool for evaluating the metabolic and interaction profiles of medications in viSvo. Over the last several decades, a number of marker drugs-that is probes-have been used for this purpose; however, midazolam, used in >70% of phenotyping cocktails, has emerged as the gold standard. 4 Advantages of midazolam include (1) oral and intravenous formulations that can be used to characterize intestinal and hepatic CYP3A metabolism, respectively; (2) a short half-life (1.0-2.8 hours) that is capable of identifying acute changes (induction or inhibition) in metabolism; (3) a favorable safety profile, typically limited to mild to moderate drowsiness, which can be further limited by the use of low or microdoses; and (4) lack of transport by P-glycoprotein (P-gp) and other transporters such as organic anion-transporting polypeptide 1B1. [5] [6] [7] For these reasons midazolam is recommended by the United States Food and Drug Administration and the European Medicines Agency as a sensitive index substrate for CYP3A metabolism. 8, 9 4β-hydroxycholesterol CYP3A4 metabolism by CYP7A1, CYP46A1, and CYP27A1, which are not involved in drug metabolism in humans ( Figure 1) . 12, 13 One of the major oxysterols is 4β-OHC.
14 4β-OHC was first described in human plasma in 1995 and was identified as a product of CYP3A4-mediated metabolism (and perhaps CYP3A5 as discussed below) in 2001. 12, 15 When 4β-OHC is considered as a CYP3A biomarker, cholesterol is the CYP3A substrate of interest, and its production and exogenous intake must be considered in addition to its CYP3A-mediated conversion to 4β-OHC. The physiologic process of lipid production and processing is complex, involving multiple pathways that are interdependent, cross-regulated, and under genetic control. 16 The liver and intestines synthesize approximately 80% of cholesterol, while 20% comes from dietary sources. 17 Cholesterol in the intestines includes dietary (ß300-500 mg) and biliary (800-1200 mg) cholesterol. Approximately 50% to 60% of intestinal cholesterol is absorbed, but there is large interindividual variability that ranges from 20% to 80%. 18 A number of dietary factors impact the degree of cholesterol absorption including the total amount of dietary cholesterol, the concentration of plant sterols, and the amount and nature of dietary fiber. 18 The typical adult synthesizes approximately 1000 mg of cholesterol daily. On average, the total body content of cholesterol is 35 g. In the United States dietary intake of cholesterol is roughly 200-300 mg per day; however, the body compensates for excess cholesterol ingestion by decreasing the amount it synthesizes. 18 Conditions such as insulin resistance, diabetes mellitus, and obesity produce marked changes in cholesterol production and absorption, which may in turn impact 4β-OHC formation. A study in male C57BL/6J mice assessed the influence of a high-fat and -cholesterol diet on oxysterols. 19 Mice in the high-fat and -cholesterol group had a mean 4β-OHC plasma concentration that was nearly 10-fold higher than that in mice receiving a normal diet (P < .001). Studies in humans and animals have shown that dietary mono-and polyunsaturated fatty acids of the (n-6) family reduce plasma cholesterol concentrations. 20, 21 To this end, diet appears to be an important determinant for 4β-OHC production; however, few studies conducted in humans have controlled for diet or excluded obese subjects. This is a key observation because diet likely has a significant influence on 4β-OHC production, which could confound the ability of 4β-OHC to accurately serve as a marker for CYP3A activity. Given the long half-life of 4β-OHC (at least 17 days; discussed in detail below), studies using this oxysterol as a CYP3A4/5 marker would need to control for diet during and several weeks before sample collection to ensure that diet is not influencing 4β-OHC concentrations, especially if 4β-OHC is used as a biomarker for a CYP3A4-metabolized drug. The relative lack of dietary control in studies conducted to date calls into question the accuracy of 4β-OHC measurement as a biomarker for CYP3A4 in these investigations.
In addition to diet, hepatic and renal disease and certain treatments associated with these conditions have been shown to modify 4β-OHC concentrations. 22, 23 Patients with chronic hepatitis C virus (HCV) infection (n = 55) had significantly elevated 4β-OHC concentrations (P < .0001) compared with 113 noninfected controls despite having lower total cholesterol. 22 After treatment of the patients with PEGylated interferon plus ribavirin for 3 months, the absolute concentration of 4β-OHC and the 4β-OHC concentration relative to cholesterol were significantly reduced in chronic HCV patients (P < .01). The authors suggested that the elevation of 4β-OHC in chronic HCV patients was due to auto-oxidation because chronic HCV infection has been associated with down-as opposed to upregulation of CYP3A4. This is noteworthy because it suggests that a disease state (chronic HCV) may modulate 4β-OHC concentrations by a mechanism that does not involve CYP3A4.
Medications that impact cholesterol levels may also alter concentrations of 4β-OHC. These include agents that can increase as well as lower low-density lipoprotein, triglycerides, or high-density lipoprotein cholesterol. Drugs that can elevate cholesterol include corticosteroids, anabolic steroids, β-blockers, amiodarone, estrogens, progestins, and human immunodeficiency virus (HIV) protease inhibitors. 24 Cholesterol-lowering agents include HMG-CoA reductase inhibitors (statins), bile-binding resins, fibrates, niacin, ω-3 fatty acids, PCS-K9 inhibitors, and the cholesterol absorption inhibitor ezetimibe. 25 Two studies assessed the influence of atorvastatin 80 mg daily for 4 weeks on 4β-OHC:cholesterol ratios in 9 gallstone patients. 26 The mean 4β-OHC:cholesterol ratio increased 12% (P < .05), which would seem to suggest weak CYP3A4/5 induction. However, the small sample size makes these study results difficult to interpret. In this same study fluvastatin 20 mg (n = 9) did not alter 4β-OHC:cholesterol ratios, nor did placebo (n = 6). 26 A second study assessed the impact of atorvastatin 20 mg × 6 months on 4β-OHC:cholesterol ratios in 15 subjects with polycystic ovary syndrome. 27 4β-OHC:cholesterol ratios decreased by 13% (P = .024). The authors concluded that atorvastatin is a CYP3A4 inhibitor; however, several study subjects were receiving additional medications, and all had polycystic ovary syndrome, either of which could potentially alter CYP3A4 activity. Of note, a previous study showed that atorvastatin 10 mg × 14 days did not influence the pharmacokinetics of midazolam or its CYP3A4-mediated metabolite 1'-hydroxymidazolam in 11 healthy volunteers, suggesting that atorvastatin does not modulate CYP3A activity. 28 Finally, endogenous cholesterol undergoes circannual variations with highest and lowest levels found in the spring and summer, respectively. 29 Hence, there are myriad variables that control the absorption, production, and trafficking of cholesterol. This in turn suggests that these same variables have the potential to impact the rate and extent of cholesterol biotransformation to 4β-OHC, which could lead to large intra-and interindividual variability in this metabolite. Diczfalusy et al present data that would seem to argue against this premise. 30 Their study of 440 subjects reported a correlation (r) between 4β-OHC and cholesterol of 0.3 (P < .0001). They note then that only 9% of the variation in 4β-OHC could be predicted by cholesterol concentration and that 91% of the variation was due to other factors such as CYP3A activity. 10 However, this poor correlation (although statistically significant) between 4β-OHC and cholesterol may be a result of the long half-life of 4β-OHC, which is due to the slow conversion of 4β-OHC to its metabolite, 4β,7α-dihydroxycholesterol. 13 As a result, acute changes in cholesterol are unlikely to be reflected in simultaneously collected plasma 4β-OHC concentrations. This is consistent with the observation that 4β-OHC concentrations appear relatively stable within subjects over short periods of time. In 12 healthy volunteers the coefficient of variation was 4.8% to 13.2% over 3 months. 31 Similarly, a second study observed percentage 4β-OHC changes from a baseline of 1.7, −8.2, 0.08, and −7.0 on days 5, 7, 14, and 30 in a group of 10 placebo recipients. 32 These data are consistent with prolonged 4β-OHC elimination; they do not necessarily suggest consistent formation of this oxysterol.
In an attempt to account for changes in cholesterol, a number of studies have chosen to report 4β-OHC:cholesterol ratios. [33] [34] [35] Habtewold et al reported 4β-OHC and 4β-OHC:cholesterol ratios at weeks 0, 4, 16, and 48 in 77 HIV-infected patients (49 patients at week 48) receiving efavirenz. 33 Median 4β-OHC levels on weeks 4, 16, and 48 increased by 140%, 177%, and 347%, respectively. 4β-OHC:cholesterol ratios increased by 257%, 291%, and 165% at these same time points. With regard to the biologic plausibility of the 4β-OHC:cholesterol data, it is difficult to understand why CYP3A4/5 activity would decrease by 32% between weeks 16 and 48 after appearing to be relatively stable between weeks 4 and 16. The reason for the differences in 4β-OHC versus 4β-OHC:cholesterol ratios was a change in total cholesterol from baseline from -29% to +46% between weeks 16 and 48. These results call into question the assumption that 4β-OHC:cholesterol ratios can be used to "correct" 4β-OHC concentrations when plasma cholesterol levels are fluctuating. This assumption does not take into account that the majority of cholesterol in the body resides intracellularly and is used for the production of bile acids (ie, it is not in the plasma).
4β-OHC Formation and Metabolism
Patients treated with the CYP3A4 inducers carbamazepine (n = 15), phenytoin (n = 10), and phenobarbital (n = 5) had plasma 4β-OHC concentrations 7-to 8-fold higher than those observed in 125 healthy volunteers (P < .0001). 12 Patients treated with valproate (n = 15), an anticonvulsant that does not induce or inhibit CYP enzymes, had 4β-OHC concentrations comparable to those detected in volunteers. A followup experiment by the same authors showed that the in vitro conversion of cholesterol to 4β-OHC was mediated by recombinant human CYP3A4; CYP1A2, CYP2C9, and CYP2B6 did not participate in this reaction. 12 A further study assessed the influence of human recombinant CYP3A4, CYP3A5, and CYP3A7 on cholesterol metabolism. 13 Relative rates of cholesterol conversion to 4β-OHC for CYP3A4, CYP3A5, and CYP3A7 were 100%, 5.6%, and 2.8%, respectively, suggesting that CYP3A4 is responsible for the majority of CYP3A-mediated cholesterol metabolism. 13 The role of CYP3A5 in the metabolism of 4β-OHC was further evaluated in vivo. 10 Plasma concentrations of 4β-OHC were measured in Tanzanians (n = 136), Swedes (n = 136), and Koreans (n = 146), all of whom underwent CYP3A5 genotyping. Within each population, the plasma concentration of 4β-OHC was significantly higher based on the number of active CYP3A5 alleles. These data suggest that CYP3A5 is an important determinant of 4β-OHC plasma concentrations, which is contrary to previously reported in vitro data that indicate a less prominent role for CYP3A5 in 4β-OHC formation. 12 However, as the authors note, in vitro systems are artificial and yield results that are more qualitative than quantitative. Collectively, these data suggest that CYP3A5 has at least a minor role in the biotransformation of cholesterol to 4β-OHC.
CYP3A4/5 comprises 30% of hepatic CYP and 80% of intestinal CYP. 2, 36 Because cholesterol metabolism primarily occurs in the liver, it has been proposed that the contribution of intestinal CYP3A is negligible in the formation of 4β-OHC. [37] [38] [39] However, Gjestad et al suggest that intestinal CYP3A4 does in fact contribute to the formation of 4β-OHC based on their finding that plasma 4β-OHC concentrations significantly correlated with carbamazepine dose (presystemic exposure) but not with steady-state carbamazepine concentrations (systemic exposure) in 55 patients receiving the drug for seizure disorders (r = 0.53, 95% CI 0.27-0.72, P < .001). 40 Despite this statistically significant finding, r 2 from this study (0.28) indicates that only 28% of the carbamazepine dose can be explained by the plasma 4β-OHC concentration. Because enterohepatic circulation of cholesterol occurs in the intestinal lumen and endogenous cholesterol and dietary cholesterol are mixed during digestion, it is possible that intestinal CYP3A4 is involved in the presystemic formation of 4β-OHC. 41 However, data are currently insufficient to predict what role intestinal CYP3A4 plays, if any, in the metabolism of cholesterol to 4β-OHC. In addition to the CYP3A-mediated formation of 4β-OHC, the further metabolism of 4β-OHC by CYP7A1 and CYP27A1 in the liver and gut must also be recognized as contributing to the plasma levels of 4β-OHC. 13, 42 Hence, any variable (ie, drug or disease state) that alters CYP7A1 and/or CYP27A1 can theoretically impact plasma concentrations of 4β-OHC, although the in vivo importance of these enzymes has been questioned. 43 Rifampin, a commonly used CYP3A inducer that is used in 4β-OHC studies (as discussed in detail below), may also modulate CYP7A1 and CYP27A1 because these enzymes along with CYP3A4 and CYP3A5 are coregulated by the pregnane X receptor. Rifampin has been shown to decrease mRNA expression of CYP7A1 in human hepatocytes, which would be expected to contribute to the elevation of 4β-OHC; this would contribute to the increase seen in 4β-OHC with CYP3A4 induction. 44 Finally, rifampin inhibits the hepatic cholesterol efflux transporter ABCA1, which could potentially impact plasma 4β-OHC concentrations. 42, 45 In summary, a number of factors in addition to CYP3A have the potential to contribute to 4β-OHC plasma concentrations.
4β-OHC Elimination
Because endogenous 4β-OHC is continually being formed via the CYP3A-mediated metabolism of cholesterol, characterizing its elimination rate is problematic. In an attempt to determine the half-life of 4β-OHC, exogenous hexadeuterated 4β-OHC was administered intravenously to 3 healthy volunteers. 13 Between 4 and 7 plasma samples were collected between 0 and 144 hours postdose, and half-lives were calculated from the logtransformed data. The data were linear (r 2 = 0.957-0.995), and the authors assumed that the time points represented the terminal elimination of the radiolabeled 4β-OHC. As such, they reported the half-lives of 4β-OHC to be 64 hours and 60 hours in the subjects devoid of concurrent CYP3A inducers and 52 hours in a female subject receiving chronic carbamazepine for a seizure disorder. However, it is unclear whether the sampling period in this study occurred during the terminal elimination phase of 4β-OHC or a distributional phase. A subsequent study attempted to characterize the elimination rate of 4β-OHC by assessing its rate of decline after a 2-week induction period with rifampin 500 mg daily (n = 2).
31 4β-OHC plasma concentrations were measured 1, 2, 4, and 8 weeks after rifampin discontinuation. Samples at 1 and 2 weeks were available in all 24 subjects, and samples were available for 10 and 8 subjects at 4 weeks and 8 weeks, respectively. The elimination rate was calculated from the last 2 time points as opposed to 3 or more time points, as is necessary to accurately characterize the terminal elimination of a medication. 46 With this methodology, the half-life was estimated to be roughly 17 days. The authors note this is likely an imprecise estimation due to the limited number of sampling points. Nonetheless, the half-life of 4β-OHC is routinely cited as 17 days throughout the literature. 35, 37, 47, 48 It is difficult to accurately assess the half-life of 4β-OHC because cholesterol is regularly produced by the body at a rate that can vary with dietary changes and medication administration. Using radiolabeled 4β-OHC is a logical approach to assessing 4β-OHC elimination; however, plasma samples would need to be collected for adequate duration and frequency to appropriately characterize the terminal elimination of the compound. Such studies would also need to contain adequate numbers of subjects, as the 2 studies discussed above included a total of 5 participants. 13, 31 What is clear is that the half-life of 4β-OHC appears to be long (days to weeks). As a result, 4β-OHC is likely to be limited in its ability to detect short-term changes in CYP3A activity. Yang et al developed a pharmacokinetic model to simulate the effect of CYP3A4 induction and inhibition on 4β-OHC plasma concentrations under different treatment durations. 49 The model assumed no changes in plasma cholesterol levels and a 17-day terminal half-life for 4β-OHC. The simulations showed that 2 weeks of dosing with a CYP3A4 inducer could potentially differentiate among weak, moderate, and potent CYP3A4 induction. However, at least 1 month of treatment with a CYP3A4 inhibitor was predicted to be necessary to differentiate among weak, moderate, and potent CYP3A4 inhibition. At least 2 weeks of treatment with a potent CYP3A4 inhibitor was predicted to be necessary to detect a 40% decrease in 4β-OHC plasma concentrations, defined as potent inhibition. The authors further recommended that 4β-OHC be normalized to total cholesterol.
Influence of CYP3A Induction on 4β-OHC and 4β-OHC:Cholesterol Ratios
A frequent aim of studies using 4β-OHC as an endogenous biomarker is to assess its usefulness in detecting CYP3A4 induction. Thirteen such studies are described in Table 1 . 12, 32, 35, 37, 40, [50] [51] [52] [53] [54] [55] [56] [57] The inducer studied most frequently was rifampin in daily doses of 10-600 mg. 32, 37, 51, 52, 54, 56, 57 Others included carbamazepine, phenytoin, phenobarbital, the comparatively weaker inducer ursodeoxycholic acid, and the CYP3A activator efavirenz. 12, 35, 40, 50, 53, 55 Most studies administered inducers for at least 2 weeks (range 1 week to months) before assessing their influence on 4β-OHC or 4β-OHC:cholesterol ratios. The majority of these investigations were conducted in healthy volunteers, although some were conducted in patients with epilepsy, gallstones, and HIV infection.
Administration of CYP3A4 inducers to inducernaive subjects routinely increased 4β-OHC or 4β-OHC:cholesterol ratios markedly above baseline in all cases (Table 1) . Rifampin 500 mg daily for 14 days resulted in a 4-fold increase in 4β-OHC levels over baseline (P < .001). 54 At lower daily doses of rifampin (20 mg and 100 mg × 14 days), 4β-OHC concentrations were still significantly elevated by 1.5-and 2.5-fold, respectively (P < .01 and P < .001). 54 A similar study showed dose-related increases in 4β-OHC:cholesterol ratios of 1.3-, 1.6-, and 2.5-fold over baseline with rifampin doses of 10, 20, and 100 mg, respectively (P < .01 for all comparisons). 37 These data suggest that 4β-OHC is able to differentiate among weak, moderate, and potent CYP3A inducers administered for 14 days to healthy volunteers. This is the same conclusion reached by a 4β-OHC pharmacokinetic model that was developed and calibrated assuming a constant cholesterol concentration and using existing literature data. 49 Two additional studies reported significant elevations in 4β-OHC of 38% and 45% after administration of the weak CYP3A4 inducer ursodeoxycholic acid 1 g daily for 3 weeks. 12, 52 Additional data suggest that CYP3A4 induction can be identified before 14 days using 4β-OHC as a biomarker. 32, 52 Rifampin 600 mg daily significantly increased 4β-OHC levels by 92% after 3 days in 1 study and by 247% after 7 days in another; both investigations were conducted in healthy subjects. 32, 52 In patients with seizure disorders, 4β-OHC concentrations were 7-to 8-fold higher in patients receiving carbamazepine, phenobarbital, and phenytoin versus those receiving the non-CYP3A inducer valproate (P < .0001). 12 Similarly, carbamazepine-treated patients with epilepsy had 4β-OHC levels that were 10-fold higher compared with patients taking the non-CYP3A4-inducing anticonvulsant levetiracetam. 40 Several studies simultaneously administered the exogenous probes midazolam and quinine when using 4β-OHC to assess CYP3A4 induction. 37, 54 Some also reported urinary 6β-hydroxycortisol:cortisol ratios as an endogenous biomarker for CYP3A4 activity; however, due to the well-described shortcomings of this approach, those data will not be discussed here. 59, 60 Bjorkhem-Bergman et al reported fold increases over baseline in midazolam oral clearance that were greater than those observed for 4β-OHC:cholesterol ratios for rifampin 10, 20, and 100 mg: 2-versus 1.3-fold, 2.6-versus 1.6-fold, and 4-versus 2.5-fold, respectively. 37 Similarly, the magnitude of reduction in oral midazolam area under the concentration-time curve (AUC) (92%) was markedly greater than the magnitude of increase in 4β-OHC concentrations (228%) after rifampin 600 mg × 14 days; the magnitude of reduction in IV midazolam AUC (51%) was closer. 32 After oral administration, midazolam pharmacokinetics reflects intestinal and hepatic CYP3A activity, whereas the respective roles of intestinal versus hepatic CYP3A on 4β-OHC biotransformation are not entirely clear as previously discussed. Moreover, due to its long halflife, 4β-OHC likely represents a weighted average of CYP3A activity over a several-day period as opposed to midazolam AUC, which represents more acute changes of CYP3A. 61 The complexity of the association between CYP3A activity and 4β-OHC concentrations is further highlighted in a study that measured concentrations of 4β-OHC, carbamazepine, and carbamazepine 10,11-epoxide over 16 weeks in 8 pediatric carbamazepine recipients newly diagnosed with epilepsy. 55 Plasma concentrations of carbamazepine and its CYP3A4/5-mediated metabolite carbamazepine 10,11-epoxide reached steady-state levels after approximately 1 week, indicating that CYP3A4/5 induction was complete. Conversely, 4β-OHC concentrations increased 86% (P = .0009) above baseline after 1 week of carbamazepine treatment and stabilized after approximately 8 weeks, at which time the 4β-OHC concentration was nearly 8-fold above baseline. These data suggest that CYP3A activity is not the only covariate regulating 4β-OHC plasma concentrations. 55 The authors note that induction of transporters by carbamazepine (ie, P-gp and ATP-binding cassette subfamily G1) could impact 4β-OHC disposition if they are involved in its transport. CYP1A2, CYP2C9, CYP2B6, and CYP2D6 have previously been shown not to metabolize 4β-OHC in vitro; however, other CYP enzymes have not been tested. Finally, as suggested earlier, auto-oxidation may contribute to 4β-OHC as well. 22 Another potential reason for differences between 4β-OHC and midazolam in their respective abilities to quantify CYP3A induction is that midazolam is not a substrate for CYP3A5, whereas 4β-OHC appears to be metabolized by this enzyme, albeit to an unknown degree. 10, 12 To this end, differences in the ability of 4β-OHC and midazolam to identify CYP3A induction are likely due to (1) differences in intestinal metabolism, (2) lack of contribution of CYP3A5 to midazolam metabolism, (3) a possible role of non-CYP3A enzymes to 4β-OHC metabolism, (4) a possible role of transport proteins as determinants of 4β-OHC concentrations at hepatic CYP3A, or (5) possible auto-oxidation contributing to 4β-OHC formation in the setting of certain disease states. Despite these confounding factors, 4β-OHC concentrations have been shown to differentiate qualitatively among weak, moderate, and potent CYP induction when administered for up to 14 days.
Influence of CYP3A Inhibition on 4β-OHC and 4β-OHC:Cholesterol Ratios
Compared with studies conducted with CYP3A4 inducers such as rifampin, fewer investigations have examined the influence of CYP3A inhibitors on 4β-OHC concentrations (Table 2) . 32 ,47,51,53,57 4β-OHC concentrations were assessed at several time points during 14 days of ketoconazole administration to healthy subjects at a dose of 400 mg daily. 32 Reductions in 4β-OHC concentrations ranged between -23% and -27% between days 5 and 14 of ketoconazole dosing. It is not clear whether these changes were statistically significant; however, the degree of CYP3A inhibition noted with 4β-OHC was relatively weak compared to changes observed using intravenous and oral midazolam as a CYP3A marker in the same study. Intravenous and oral midazolam AUC values were increased by 11-fold and 5-fold, respectively after 14 days of ketoconazole administration. An additional study examined the influence of ketoconazole 400 mg daily for 4 days on 4β-OHC concentrations. 51 An average decrease of 16.7% was observed in 4β-OHC concentrations between baseline and day 4 of ketoconazole administration. Of note, 2 subjects actually experienced increases in 4β-OHC concentrations, and 1 subject experienced a change of -0.6%. A similar study found a 7% decrease in 4β-OHC:cholesterol ratios compared with baseline after 4 days of ketoconazole 400 mg in healthy subjects. 57 Intravenous midazolam AUC was increased by 2.83-fold over baseline in this same study. These data indicate that 4β-OHC is neither a sensitive nor reliable marker of CYP3A inhibition using the potent CYP3A inhibitor, ketoconazole.
The impact of itraconazole on 4β-OHC concentrations was reported in 8 patients with onychomycosis. 47 Subjects received itraconazole 400 mg daily for an average of 8.5 days, then they repeated this cycle with nearly a 3-week washout period in between. Similar reductions in 4β-OHC of 27% and 31% were found after both itraconazole treatment cycles (P = .0028 and .0118, respectively). Reductions in 4β-OHC:cholesterol ratios after each treatment cycle were also found to be significantly different compared with baseline (−18.5% [P = .0105] and −23.1% [P = 0.0118], respectively). Similar degrees of reduction (-11% to −18%) in plasma 4β-OHC concentrations were reported after administration of the potent CYP3A4 inhibitor ritonavir (100-200 mg per day in combination with lopinavir and atazanavir, respectively) to antiretroviral-naive HIVinfected patients for 4 weeks. 53 The minimal changes in 4β-OHC concentrations among lopinavir-ritonavir (LPV/r)-treated patients were postulated to be due to concurrent CYP3A4 induction by lopinavir. However, if this were true, we would also expect to see minimal changes in midazolam AUC after LPV/r administration. Although midazolam was not administered in the current study, a previous investigation in 14 healthy subjects observed a 92% reduction in oral midazolam clearance (Cl/F) after 14 days of LPV/r administration. 61 Hence, a recurring theme is that reductions in 4β-OHC concentrations observed with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir are far less in magnitude (about −10% to −30%) than changes observed when these inhibitors are coadministered with midazolam. The prolonged elimination of 4β-OHC most likely contributes to slow rises in 4β-OHC concentrations in the presence of CYP3A inhibition. Indeed, using the pharmacokinetic model they developed, Yang and Rodrigues postulated that lengthy durations of CYP3A inhibitor administration (ie, ࣙ1 month) would be necessary to differentiate among weak, moderate, and potent CYP3A inhibitors. 49 Multiple linear regression was employed to evaluate a number of covariates on CYP3A activity as assessed by 4β-OHC concentrations in 655 patients seen at a psychopharmacology hospital. 62 One of the covariates was defined as treatment with CYP3A inhibitors as included on the Flockhart Cytochrome P450 Drug Interaction Table. 63 Treatment with inhibitors was associated with 4β-OHC levels that were 34% less than the estimated level in the reference population (P = .021). 62 Inhibitors were present in 18 subjects and included fluoxetine (n = 16) and fluvoxamine (n = 2), which are reported to be weak to moderate CYP3A inhibitors. Patients in this study were stabilized on these medications long-term. The degree of reduction in 4β-OHC concentrations (−34%) was similar to that observed in subjects receiving the potent CYP3A inhibitor itraconazole over a shorter time period (−19% to −31%).
47

Relationship Between 4β-OHC Concentrations (and Ratios) and Exogenous Probes
A number of studies have reported the linear relationship (using r and/or r 2 values) between 4β-OHC concentrations and/or ratios and midazolam clearance (Table 3) . 30, 37, 48, 54, 57, 60, 64 Quinine:3-hydroxyquine ratios have also been assessed for their linear relationship to 4β-OHC and/or 4β-OHC:cholesterol ratios. 30, 54 Bjorkhem-Bergman et al reported an r 2 value of 0.29 for oral midazolam clearance versus 4β-OHC:cholesterol ratios (P < .01). 37 Similarly, Shin et al reported an r 2 of 0.38 for intravenous midazolam clearance versus 4β-OHC (P < .01). 57 TomalikScharte et al also reported statistically significant correlations for oral and intravenous midazolam clearance versus 4β-OHC and 4β-OHC:cholesterol ratios; r 2 values ranged from 0.06 to 0.12 (1-sided P value <.05 for all comparisons). 60 Last, 4β-OHC was shown to correlate poorly (r 2 = 0.06; P = .081) to oral midazolam clearance predicted from a single time point after a 100-μg dose of midazolam to 51 volunteers. 64 All of these studies were conducted in healthy subjects with constitutive CYP3A activity (ie, not receiving CYP3A inhibitors or inducers).
Weight-corrected midazolam Cl/F and total clearance were correlated with weight-corrected 4β-OHC:C in 147 and 70 stable renal transplant recipients, respectively. 48 The r 2 value for weight-corrected oral midazolam versus weight-corrected 4β-OHC:C was 0.24 (P < .001), which is similar to that reported by Bjorkhem-Bergman et al in healthy subjects (r 2 = 0.29). 37 The r 2 value for weight-corrected intravenous midazolam versus weight-corrected 4β-OHC:C was 0.16 (P = .001).
It is important to note that although correlation coefficient (r) and coefficient of determination (r 2 ) measure the strength of a linear relationship between 2 variables, they do not measure agreement between them, and they do not measure predictive performance. [65] [66] [67] When investigators compare 2 methods (ie, midazolam clearance and 4β-OHC or 4β-OHC: cholesterol ratios) over the range of typically encountered values, a significant correlation is almost certain because the null hypothesis is that the measurements are not linearly related. 67 Hence, as stated by Bland and Altman, "it would be amazing if two methods designed to measure the same quantity were not related. The test of significance is irrelevant to the question of agreement." 67 In this case "quantity" refers to CYP3A activity. To this end, when 2 methods to quantitate CYP3A activity are compared, r or r 2 values are often overvalued and do not substantiate that a CYP3A marker (ie, 4β-OHC or 4β-OHC:cholesterol ratio) is valid for widespread use.
To assess the ability of 4β-OHC or 4β-OHC:cholesterol ratios to measure CYP3A activity (ie, predictive performance), 1 or both of these should be compared with the "gold standard" for this measurement, which is midazolam clearance.
8 Predictive performance should be assessed by measuring precision and bias in addition to r 2 as discussed in detail by Sheiner and Beal. 66 Precision and bias are assessed using mean squared prediction errors and median prediction errors, respectively. The regression slope is plotted against unity as an indicator of accuracy. Of note, this assessment should occur not only during constitutive CYP3A production but also under conditions of CYP3A inhibition and induction, as any test should be validated over its intended range of use. 68 Perhaps most important is the issue of sample size. Sample size is an important determinant of the precision of r 2 , and an adequately powered study is needed to characterize the magnitude of a biological association. 68 A small sample size may yield an imprecise estimate of r 2 . As an example noted by Kharasch et al, 68 in a study with an adequate sample size (n = 95), midazolam and alfentanil clearances in subjects with constitutive CYP3A activity were significant (r 2 = 0.60, P < .001), demonstrating that 60% of the variability in alfentanil clearance was predicted by midazolam clearance, and vice-versa. 69 Notably, the sample sizes in Table 3 ranged between 15 and 24 for 4 of the 8 studies included, suggesting that these studies may not have been adequately powered, which may have negatively impacted the precision of the measured r 2 value. 68 Last, poor correlations are expected when 1 probe is administered orally and the other intravenously because CYP3A activities in the liver and intestines do not correlate. [68] [69] [70] [71] 4β-OHC levels and 4β-OHC:cholesterol ratios represent an interesting situation because, as an endogenous biomarker, cholesterol is administered neither orally nor intravenously, and, as discussed, the role of intestinal CYP3A on 4β-OHC formation is unclear. Tomalik-Scharte et al report correlations between 4β-OHC and 4β-OHC:cholesterol ratios versus both intravenous and oral midazolam clearance. 72 In accordance with previously published data, tacrolimus Cl/F plasma decreased during the first 2 months posttransplant. This is hypothesized to be due to the waning effects of glucocorticoid-induced induction of CYP3A and P-gp as these drugs are tapered during the posttransplant period; an increase in hematocrit is also known to contribute. Contrary to what was expected, 4β-OHC concentrations actually increased with time after transplantation, suggesting an increase (as opposed to a decrease) in CYP3A activity. Suzuki et al also noted increases in 4β-OHC concentrations in 13 renal transplant recipients posttransplant; however, these increases were not significantly different from pretransplant values until 90 days posttransplant. 73 A retrospective study was conducted to confirm the results of Storset et al in 279 renal transplant patients in the first 14 days after transplant. 74 In their analysis the only significant determinant of tacrolimus dose and absolute or dose-corrected tacrolimus trough concentrations was CYP3A5 genotype; 4β-OHC concentrations determined immediately before transplant were not related to tacrolimus dose requirement or dosecorrected tacrolimus concentration during the 14-day study period. The investigators of this study propose that preoperative uremia and complex and variable perioperative clinical variables precluded the ability of 4β-OHC to predict tacrolimus dose or concentrations. 43 In contrast to results from these tacrolimus studies, phenotyping with both oral and intravenous midazolam predicted a decrease in CYP3A activity in the early posttransplant period (week 1 versus week 4). The decrease in apparent oral clearance between week 1 (n = 35) and week 4 (n = 29) explained 55.4% of the decrease in tacrolimus clearance in the first month after transplant (−21%; P < .001). 76 This study did not collect 4β-OHC plasma concentrations. Collectively, these studies suggest that 4β-OHC is not useful in predicting CYP3A changes in the first 2 months after transplantation. This may be due to perioperative clinical changes and the long half-life of 4β-OHC, which is not sensitive to acute changes in CYP3A activity. Midazolam has shown success in explaining tacrolimus clearance during the first 30 days posttransplant.
VanHove et al characterized the relationships among weight-corrected tacrolimus clearance, 4β-OHC:cholesterol, intravenous midazolam clearance, and apparent oral midazolam clearance (all weight corrected). 48 Seventy patients underwent intravenous midazolam phenotyping and 147 patients participated in the remainder of the study. Weight-corrected intravenous midazolam clearance was significantly correlated with tacrolimus clearance (r 2 = 0.26; P < .001), as was weight-corrected apparent oral midazolam clearance (r 2 = 0.07; P = .001) and weight-corrected 4β-OHC:cholesterol (r 2 = 0.17; P < .001). Midazolam-and 4β-OHC:cholesterol-based multivariate regression models explained 48% to 59% and 31% to 51% of the interindividual variability in tacrolimus clearance, respectively. Most likely, the associations observed in this study reflect the stable nature of the patient population; that is, they were not undergoing steroid treatment, and they likely had fewer medical complications than those seen in the early (1 month) posttransplant period.
Quetiapine
The correlation between 4β-OHC and dose-adjusted steady-state trough concentrations of the CYP3A4 substrate quetiapine was assessed in 151 psychiatric patients treated with immediate-release (n = 98) or slow-release (n = 53) quetiapine. 77 The r 2 value between quetiapine dose-adjusted concentration and 4β-OHC was 0.26 for pooled immediate-release and slow-release data. In a multilinear regression model the model fit r 2 was 0.28 and included 4β-OHC, sex, age, and drug formulation (immediate release versus slow release). Hence, the model explained approximately 30% of the variability in the dose-adjusted serum concentration of quetiapine. These data are similar to those reported for tacrolimus in stable renal transplant patients (ie, both showed a significant correlation between steady-state concentrations of a drug and 4β-OHC). 48 Despite the statistical significance of these correlations, they vary based on exposure to different substrates and disease states, and as discussed, correlations tend to be overvalued. 66, 67 Moreover, it is unclear how data from this investigation (eg, knowing that 25% to 30% of a dose-adjusted quetiapine concentration can be explained by 4β-OHC level) can practically be implemented to individualize quetiapine dosing. Also, as Gjestad et al note, the clinical implementation of 4β-OHC concentrations to serve as a generic biomarker that can predict individual dosing requirements for all CYP3A4 substrates is not realistic.
78
Biological Disease-Modifying Antirheumatic Drugs Patients with rheumatoid arthritis have been shown to have reduced CYP3A activity due to downregulation of this enzyme by inflammatory cytokines including tumor necrosis factor α, interleukin (IL)1β, interferon γ , and most importantly IL6. 79 In a recent study 4β-OHC concentrations were measured in 41 rheumatoid arthritis patients to assess CYP3A phenotype before and 2-5 months after starting therapy with biological disease-modifying antirheumatic drugs (bDMARDs). 80 Treatment with bDMARDs was hypothesized to result in regained CYP3A phenotype as measured by 4β-OHC. Contrary to expectations, 4β-OHC concentrations did not differ after initiation of bDMARDs (50 versus 52 nmol/L; P = .6). The bDMARDs used in this study were tumor necrosis factor α inhibitors (n = 31), IL6 inhibitors (n = 5), and B-cell inhibitors (n = 5). There was no observed tendency for regained CYP3A phenotype in the 5 patients treated with the anti-IL6 inhibitor tocilizumab. Of note, IL-6 is the interleukin thought to have the most potent inhibitory effect on CYP3A activity. 81 In contrast to these findings, midazolam AUC was reduced 30% to 35% (upper confidence bounds of geometric mean ratios were less than 1.0) 1, 3, and 6 weeks after initiation of treatment with the anti-IL6 monoclonal antibody sirukumab. 82 This study was conducted in 12 rheumatoid arthritis patients. Although the study by Wollman et al included only 5 patients receiving IL-6 inhibitors, it is noteworthy that 4β-OHC concentrations did not show an increase in CYP3A activity as was seen with midazolam in a separate study. 80, 82 The reason for the negative results in the Wollman study likely reside in the fact that the offset of CYP3A4 inhibition represents a more or less acute change in CYP3A activity that, as previously discussed, is not readily detected by 4β-OHC due to its prolonged half-life.
Taxanes
The taxanes paclitaxel and docetaxel are metabolized by CYP3A4, and both show significant interpatient pharmacokinetic variability. Therefore, de Graan et al assessed the ability of 4β-OHC to predict individual taxane pharmacokinetics of these narrow therapeutic agents. 83 In a paclitaxel cohort of 291 patients, no significant correlations were found between 4β-OHC or 4β-OHC:cholesterol ratios and paclitaxel clearance (P > .4). The outcome did not change when data were analyzed separately for male and female subjects. A weak but significant correlation was found between 4β-OHC and docetaxel clearance only in men (r 2 = 0.12; P = .001). The authors concluded that 4β-OHC has limited value for predicting dose individualization with taxanes based on these results. Conversely, intravenous midazolam clearance was found to correlate significantly with docetaxel clearance in 31 patients with solid malignancies. 84 Although this was not studied head to head, there appear to be definite differences in the ability of 4β-OHC and midazolam to predict taxane clearance; however, the clinical utility of either phenotyping method for this purpose is unclear.
Conclusion
A number of publications have described criteria for assessing agreement between 2 methods of clinical measurement; however, no investigations have followed these predictive performance suggestions in adequately powered studies that include 4β-OHC and/or 4β-OHC:cholesterol ratios and the gold standard CYP3A phenotyping method, midazolam clearance. [65] [66] [67] It has been recommended that 4β-OHC concentrations may be useful as biomarkers for detecting CYP3A activity in a number of situations including (1) chronic conditions in which CYP3A activity is altered by disease and (2) long-term treatment studies in patient populations in which midazolam administration is not feasible. 39 However, we do not believe that current data with 4β-OHC support this recommendation. Currently, the most logical use for 4β-OHC would be as a biomarker to detect induction after at least 2 weeks of treatment with a new molecular entity; however, even in this case, larger studies with 4β-OHC and midazolam that report predictive performance (ie, precision and bias) are needed before such an approach should be widely adopted. 11 As noted in this article and elsewhere, the magnitude of change in 4β-OHC is likely to be lower than that in midazolam clearance when both phenotyping methods are employed in a drug interaction study. 39 Hence, midazolam clearance appears to be advantageous over 4β-OHC in terms of accuracy in predicting the magnitude of a drug-drug interaction. 4β-OHC provides more of a qualitative as opposed to a quantitative estimate in such studies. Because of the limitations associated with 4β-OHC phenotyping, which include the inability to detect acute changes in CYP3A activity, uncertainty with regard to its intestinal formation, ambiguity surrounding the role of CYP3A5 in its metabolism, and lack of clarity regarding the role of transporters in its disposition, results from studies reporting 4β-OHC concentrations will frequently be met with uncertainty. As a result, 4β-OHC should not be used as a CYP3A phenotypic marker.
Last, common concerns with exogenous probes such as midazolam or alfentanil include safety concerns, particularly in certain patient populations such as pediatric and cancer patients, and the burden of cost. Generally, such concerns tend to be overstated. Midazolam phenotyping can be conducted after a single dose (or microdose to minimize side effects) with a minimal number of samples over 8-12 hours; typically, this process need only be conducted twice, once before and once after treatment with a putative modulator of CYP3A. 64 Limited sampling strategies that minimize plasma collection are a reality as well. 85 Alfentanil phenotyping can be conducted using the noninvasive method of measuring pupillary miosis. 86 Unlike 4β-OHC biomarker studies, both of these CYP3A markers yield definitive results that do not require follow-up studies. With regard to costs associated with phenotyping studies during the drug development process, typically the cost of such studies, conducted in a limited number of healthy volunteers, is a minute fraction of the total cost of drug development. To this end, use of 4β-OHC or 4β-OHC:cholesterol ratios cannot be recommended as an endogenous biomarker for the assessment of CYP3A activity.
